XML 23 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 1,410.1 $ 769.0
Short-term investments (Note 5) 453.8 446.3
Accounts receivable, net of allowances of $7.9 and $7.9, respectively 739.8 643.0
Other receivables 62.3 56.1
Inventories (Note 2) 1,032.4 875.5
Prepaid expenses 133.3 110.0
Other current assets 235.8 195.9
Total current assets 4,067.5 3,095.8
Long-term investments (Note 5) 704.6 1,239.0
Property, plant, and equipment, net 1,681.3 1,632.8
Operating lease right-of-use assets 90.9 92.3
Goodwill 1,297.4 1,164.3
Other intangible assets, net (Note 7) 429.8 285.2
Deferred income taxes 651.9 484.0
Other assets (Note 6) 447.4 299.1
Total assets 9,370.8 8,292.5
Current liabilities    
Accounts payable 190.6 201.9
Accrued and other liabilities (Note 2) 1,024.0 795.0
Operating lease liabilities 24.3 25.5
Total current liabilities 1,238.9 1,022.4
Long-term debt 596.8 596.3
Contingent consideration liabilities (Note 8) 0.0 26.2
Taxes payable 81.2 143.4
Operating lease liabilities 70.0 69.5
Uncertain tax positions 312.1 267.5
Litigation settlement accrual 104.4 143.0
Other liabilities 240.3 217.5
Total liabilities 2,643.7 2,485.8
Commitments and contingencies (Note 12)
Stockholders' equity    
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding           0.0 0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 649.9 and 646.3 shares issued, and 606.5 and 608.3 shares outstanding, respectively 649.9 646.3
Additional paid-in capital 2,211.3 1,969.3
Retained earnings 8,622.5 7,590.0
Accumulated other comprehensive loss (Note 13) (250.1) (254.9)
Treasury stock, at cost, 43.4 and 38.0 shares, respectively (4,576.1) (4,144.0)
Total Edwards Lifesciences Corporation stockholders' equity 6,657.5 5,806.7
Noncontrolling interest (Note 7) 69.6 0.0
Total stockholders' equity 6,727.1 5,806.7
Total liabilities and equity $ 9,370.8 $ 8,292.5